121637-13-6

Basic information

• Product Name: (S)-6-[(S)-2-Hydroxy-3-(naphthalen-1-yloxy)-propylamino]-heptanoic acid p-tolylamide
• CAS NO: 121637-13-6
• Molecular Weight: 434.579
• Mol File: 121637-13-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-6-[(S)-2-Hydroxy-3-(naphthalen-1-yloxy)-propylamino]-heptanoic acid p-tolylamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-6-[(S)-2-Hydroxy-3-(naphthalen-1-yloxy)-propylamino]-heptanoic acid p-tolylamide(121637-13-6)
• EPA Substance Registry System: (S)-6-[(S)-2-Hydroxy-3-(naphthalen-1-yloxy)-propylamino]-heptanoic acid p-tolylamide(121637-13-6)

Safety Data

• Hazardous Substances Data: 121637-13-6(Hazardous Substances Data)

Upstream product

• 61249-00-1 (S)-(1-naphthyl) glycidyl ether 
• 125452-32-6 (S)-6-aminoheptanoic acid p-toluidide 
• 90-15-3 α-naphthol 

Relevant articles and documents

Synthesis and β-Adrenergic Antagonist Activity of Stereoisomeric Practolol and Propranolol Derivatives

A series of stereoisomeric practolol and propranolol derivatives has been synthesized in which the N-isopropyl group of the drug was replaced by an asymmetric heptanoic acid terminated by a substituted p-toluidide of p-(tri-fluoromethyl)anilide.The asymmetric epoxide, 3-(p-acetamidophenoxy)-1,2-epoxypropane, was allowed to react with a preformed enantiomeric 6-aminoheptanoic acid amide to yield the stereoisomeric practolol congener derivatives.An asymmetric drug precursor epoxide was prepared from p-acetamidophenol and enantiomeric 3-(tosyloxy)-1,2-epoxypropane (the Sharpless epoxide).For the propranolol congener derivatives, the preformed asymmetric 6-aminoheptanoic acid amides were allowed to react with one of the enantiomers of 3-(1-naphthyloxy)-1,2-epoxypropane.This drug precursor epoxide was prepared either by combining 1-naphthol with enantiomeric 3-(tosyloxy)-1,2-epoxypropane (the Sharpless epoxide) or by combining 1-naphthol with enantiomeric 3-(tosyloxy)-1,2-propanediol followed by epoxidation.Pharmacological studies carried out for the practolol derivatives demonstrated a significant dependence of enhanced potency and tissue/subreceptor specificity on both the configuration of the drug asymmetric carbon and the configuration of the spacer asymmetric carbon.The compounds containing the S configuration at the drug asymmetric center and the R configuration at the spacer asymmetric carbon exhibited an increase in potency over the other stereoisomeric congener derivatives and the progenitor drug.For the propranolol congener derivatives, a large decrease in potency was observed for all of the stereoisomers over the progenitor drug.The propranolol stereoisomers containing the S configuration at the drug asymmetric center were more active than those containing the R configuration at that center.